Results 11 to 20 of about 16,360 (195)
Summary: Background: Abatacept is a selective T-cell costimulation modulator approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis.
Xiaozhen Geng
exaly +3 more sources
Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis. [PDF]
ObjectivesAbatacept acts as a competitive inhibitor of the CD28/(CD80/86) costimulation signal required for T cell activation. Mechanisms of action of abatacept have not been fully investigated. The objective of this study was to provide detailed insight
Céline Derambure +4 more
doaj +2 more sources
Chadi Rakieh, Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UKAbstract: Biologic therapies in rheumatoid arthritis are now part of standard ...
Rakieh C, Conaghan PG
doaj +1 more source
Abatacept as maintenance therapy in kidney transplantation: a retrospective comparative study [PDF]
Belatacept use is increasinging in kidney transplantation, as it has demonstrated improved graft survival compared with calcineurin inhibitors. However, its intravenous administration and recurrent supply shortages may limit its use.
Charlotte Uro-Coste +15 more
doaj +2 more sources
Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy [PDF]
Ofra Goldzweig1, Philip J Hashkes2,31Rainbow Babies and Children's Hospital, Cleveland, OH, USA; 2Pediatric Rheumatology Unit, Shaare Zedek Medical Center, Jerusalem, Israel; 3Cleveland Clinic Lerner Medical School of Case Western Reserve ...
Ofra Goldzweig, Philip J Hashkes
doaj +2 more sources
Introduction One target of rheumatoid arthritis (RA) treatment is to achieve early sustained remission; over the long term, patients in sustained remission have less structural joint damage and physical disability.
Paul Emery +14 more
doaj +1 more source
Background To evaluate incidence of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with abatacept in clinical trials.
Teresa A. Simon +2 more
doaj +1 more source
Background AVERT-2 (a phase IIIb, two-stage study) evaluated abatacept + methotrexate versus methotrexate alone, in methotrexate-naive, anti-citrullinated protein antibody-positive patients with early (≤ 6 months), active RA.
Paul Emery +12 more
doaj +1 more source
Background Abatacept is a recombinant fusion protein composed of the extracellular domain of cytotoxic T-lymphocyte antigen 4 and the Fc portion of immunoglobulin (Ig) G. The mechanism of action of abatacept in rheumatoid arthritis (RA) is believed to be
Ryosuke Fukue +3 more
doaj +1 more source
Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain [PDF]
Objective: To compare the cost of treating rheumatoid arthritis patients that have failed an initial treatment with methotrexate, with subcutaneous aba - tacept versus other first-line biologic disease-modifying antirheumatic drugs. Method: Subcutaneous
R. Ariza +6 more
doaj +1 more source

